Cardio-Protective Effect of Saxagliptin and Dapagliflozin Combination on Endothelial Progenitor Cells in Patients with Type 2 Diabetes

We are looking if Saxagliptin and Dapagliflozin, which are FDA approved Diabetes medications, will improve your cardiovascular health. We are looking for patients who are between 30-70 years of age with HbA1c from 7 to 10%, who are taking Metformin and/or Insulin only for their Diabetes.

Sponsor(s)
Astra Zeneca Pharmaceuticals, LP
Principal Investigator(s)
Saby Sen, MD, PhD
Contact Phone Number
Request Information
Address

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

7 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.